First-to-market
Immunology
LaunchFDAEMA
Approved by reference regulators, already generic abroad, and not yet registered in Pakistan.
Full analysis for subscribers
Find your next launch
before your competitors do.
RxScout scouts global approvals, patents, pipelines and deals, then tells your business-development team exactly what to launch, in-license or partner on next in Pakistan.
- Every FDA & EMA-approved molecule
- Refreshed every day
- Built for pharma BD teams
- 0
- Molecules screened
- 0
- Pipeline assets tracked
- 0
- Patent windows
- 0
- Market signals
How RxScout thinks
From market intelligence to BD decisions
Intelligence
- Approvals & patentsWho is approved, who is protected
- Local marketWho already competes in Pakistan
- Clinical pipelinesWhat is coming next
- SafetyRisks to know early
- Science & dealsMomentum and partnering moves
RxScout
- Market Opportunity Score
- Clear recommendation
- Evidence behind every call
Refreshed daily
Decisions out
- Launch candidates917
- In-licensing targets745
- Patent windows165
- Phase 3 assets1,100
- Market signals1,907
BD decisions shouldn't take weeks of spreadsheets
Deciding what to launch means cross-checking approvals, patents, local competitors and pipelines. Done by hand, it is slow and out of date by the time it is finished. RxScout gives you the answer, ready to act on.
The usual way
- Checking regulators one molecule at a time
- Patent and exclusivity dates hard to find and easy to miss
- Late to new pipeline assets and licensing deals
- Opportunity lists out of date the day they are made
With RxScout
- 2,333 approved molecules and combinations screened for Pakistan
- Patent windows and new generic entries surfaced months ahead
- 2,920 pipeline assets tracked, including 643 from Asian developers
- Ranked, explained recommendations refreshed every day
The Market Opportunity Score
One number, fully explained
Every molecule gets a 0–100 score from objective market signals, plus a plain recommendation: Launch, In-license, Fast-follow, Monitor or Avoid. Open any molecule to see exactly why.
- Local whitespace. How many companies already sell the exact product in Pakistan. Zero means first-to-market.
- IP freedom. Patent and exclusivity status, and whether generics are already approved.
- Reference approvals. Approval by stringent reference regulators such as the FDA and EMA.
Local whitespace
32.5%
Reference approvals
17.5%
IP freedom
17.5%
Global validation
17.5%
Momentum
15%
Then adjusted for risk, such as recalls, withdrawals and price control.
Opportunity snapshot
A glimpse inside the screener
Three of today's results, anonymised. Subscribers see the molecule, the evidence and the full analysis.
89
In-licensing target
CNS & Psychiatry
In-licenseFDAEMA
Still patent-protected with little local competition. The route in is a licence.
Full analysis for subscribers
Crowded market
Gastroenterology
Fast-followFDAEMA
Many local registrations already. Flagged before your team invests months in a me-too launch.
Full analysis for subscribers
Pipeline Radar
Spot licensing partners early
See Phase 2 and Phase 3 assets that are not yet approved in the US or EU, and who is developing them. Mid-size developers in China, Korea, India and Japan often out-license regional rights: RxScout shows you where to look first.
0
assets tracked
0
in Phase 3
0
Asian developers
Global
2,277
China
512
South Korea
57
Japan
57
India
17
Phase 2/3 assets not yet approved in the US or EU.
Everything in one place
Built for pharma business development
Opportunity Screener
Every approved molecule and combination ranked by Market Opportunity Score, filterable by therapy area, local competition, IP status and dosage form. Export to Excel in one click.
Pipeline Radar
Phase 2 and Phase 3 assets not yet approved in the US or EU, with developer, region and trial activity, so you can start licensing conversations before competitors do.
Market Signals
Patent and exclusivity windows, new approvals, generic entries, Phase 3 completions, recalls and licensing moves, as they happen.
AI Due-Diligence Dossiers
Referenced briefs covering regulatory status, patents, local competitors, potential partners, deals and risks.
Weekly BD Brief
A concise weekly brief for leadership: the strongest launch candidates, in-licensing targets and the market moves that matter.
Built for BD teams
Plain-language recommendations (Launch, In-license, Fast-follow, Monitor, Avoid) with the evidence behind every score. No data-science skills needed.
Pricing
Start free. Go live when you are ready.
One simple paid plan. Cancel any time.
On Free, signals and rankings are 30 days behind. Pro is live, so you see opportunities the day they appear.
Free
$0forever
See how RxScout works, with signals and rankings 30 days behind.
- Signals and rankings: 30 days behind the market
- Opportunity Screener: All molecules; scores, recommendations and Pakistan competition locked
- Top launch candidates: Top 3 preview
- Molecule deep-dives: 3 per month
- Market signals: Delayed 30 days
- Pipeline Radar: Totals only
- Weekly BD brief: Headline only
- Due-diligence dossiers: 1 sample
- Excel export: Not included
- Watchlist: 5 molecules
Pro
Live dataPKR16,000per month
Everything in RxScout, live and unlocked.
- Signals and rankings: Live, refreshed daily
- Opportunity Screener: Everything unlocked
- Top launch candidates: All candidates
- Molecule deep-dives: Unlimited
- Market signals: Real-time
- Pipeline Radar: Full asset list and developers
- Weekly BD brief: Full brief
- Due-diligence dossiers: Full library
- Excel export: Included
- Watchlist: Unlimited
Getting started
Up and running in minutes
- 1
Create a free account
Sign up with your work email. No card needed.
- 2
Explore
Browse every approved molecule and preview the top launch candidates, 30 days behind the market.
- 3
Go live with Pro
Unlock every score, live signals, the full pipeline and dossiers for PKR 16,000 a month.
Frequently asked questions
How often is it updated?+
Daily. New opportunities, pipeline assets and market signals appear in your workspace every day.
What is the Market Opportunity Score?+
A 0–100 score that summarises how attractive a molecule is for your market. It weighs local competition, reference approvals, patent and exclusivity freedom, proven global demand and momentum, adjusted for risk.
Is RxScout specific to Pakistan?+
Recommendations are tailored to the Pakistani market. Global coverage of approvals, patents, pipelines and deals is useful for any market.
Is this investment, legal or clinical advice?+
No. RxScout is decision support. Scores and dossiers should be validated commercially, legally and regulatorily before acting.
What is the difference between Free and Pro?+
Free lets you browse every approved molecule, preview the top 3 launch candidates and open 3 molecule deep-dives a month, with signals and rankings 30 days behind. Pro is live and unlocks every score, recommendation, Pakistan competitor count, signal, pipeline asset, brief, dossier and Excel export for PKR 16,000 a month.
How do I get started?+
Create a free account with your work email. On the Free plan, signals and rankings are 30 days behind and scores are locked; upgrade to Pro for PKR 16,000 a month any time for live data and everything unlocked.